RTOG Foundation Newsletter

Fall 2025

info@rtog.org

In this Issue:

Interview with Dr. Stephen Chun
Meet the RTOG Foundation Communications Interns
Lung Cancer with Dr. Jeff Bradley
RTOGF at ASTRO 2025
RTOG 3521 Update

An Interview with Dr. Stephen Chun

Our RTOG Foundation Communications Interns recently sat with NRG Oncology co-host and co-founder, Stephen Chun, MD, to discuss his career pathways so far and his involvement in RTOG Foundation and NRG Oncology. Dr. Chun is a radiation oncologist practicing at the MD Anderson Proton Center and the West Houston Campus. He is the Director of Radiation Oncology Clinical Research at the MD Anderson Houston area locations.

Read the interview

Meet the 2025-2026 RTOGF Communications Interns

RTOG Foundation (RTOGF) recently selected two communications interns to help RTOGF create social media content around RTOGF clinical trials. The internship is a 12-month position starting July 1, 2025 and will allow each intern a way to get more involved with the RTOGF organization and cancer research. Interns will be also attending virtual meetings with the RTOGF Communications Committee, attending RTOGF Board Meetings, and have the opportunity to attend an RTOGF Investigators Meeting as well as the NRG Oncology Meetings.

The NRG Oncology Podcast Interviews Dr. Jeff Bradley on Lung Cancer Research and Mentorship

NRG Oncology Podcast co-hosts Dr. Stephen Chun and Dr. Lauren Henke interviewed Dr. Jeffrey Bradley on his tenure as long-time Lung Cancer Committee Chair in light of the recent announcement that he would be stepping down from his position. Dr. Bradley discusses the past, present, and future of lung cancer research and shares his personal goal to mentor the future leaders in the field. You can listen to the full podcast episode at www.NRGOncology.org/Podcast.

RTOGF at ASTRO 2025

For the first time, the RTOG Foundation hosted an organizational overview session at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco. Held on Monday, September 29th in the Early Career & Mentoring Lounge, the session featured RTOG Foundation Board Members who introduced the organization, highlighted its research initiatives, and shared guidance on how to get involved in clinical trials. The presentation was followed by a networking opportunity and an open Q&A with attendees.

Read the full recap and find press releases here

Update on RTOG 3521 (the 'TRANSPARENT" study)

CHS-007-01/RTOG 3521 (Transparent trial) is a single-arm, multicenter, Phase IV study assessing the efficacy and safety combination of the anti-PD1 toripalimab and chemotherapy (cisplatin and gemcitabine) in a North America patient population of patients with nasopharyngeal carcinoma who are systemic treatment-naïve in the recurrent/metastatic setting. RTOG 3521trial’s primary objective is objective response rate. A key secondary objective is to assess the duration of response of chemo-immunotherapy followed by adjuvant toripalimab for a total duration of therapy of up to 2 years. The study, currently open to accrual since October 31,2024, aims to include 100 patients, representing various subtypes of nasopharyngeal cancer (EBV-positive or negative, HPV-positive or negative, or double-negative), all of whom are systemic therapy-naïve in the recurrent/metastatic setting.

Did You Know?

There are several ways you can participate in RTOG Foundation as a member site, an industry collaborator, or by enrolling in one of our studies. Read more on our website about how you can partner with RTOG Foundation.

Learn more at www.RTOG.org/Partners